Arcutis Biotherapeutics, Inc. (ARQT) vs Relay Therapeutics, Inc. (RLAY)
- Arcutis Biotherapeutics, Inc. ARQT 28.82 −0.96%
- Relay Therapeutics, Inc. RLAY 16.28 −5.90%
Arcutis Biotherapeutics, Inc. and Relay Therapeutics, Inc. are both Biotechnology companies. Arcutis Biotherapeutics, Inc. and Relay Therapeutics, Inc. are of similar size ($3.8B and $3.7B). Relay Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; Arcutis Biotherapeutics, Inc. trades at 131×. Arcutis Biotherapeutics, Inc. grew revenue faster over the last twelve months: 76.1% against −74.3%. Arcutis Biotherapeutics, Inc. has the higher net margin (6.15% vs −2,594.2%) and the higher return on invested capital (23.6% vs 0.00%). Across the 17 metrics below, Arcutis Biotherapeutics, Inc. leads on 12 and Relay Therapeutics, Inc. on 5.
Valuation
Profitability
| Metric | ARQT | RLAY | Biotechnology median |
|---|---|---|---|
| Gross margin | 91.14% | 100.00% | 65.16% |
| Operating margin | 7.38% | (2,815.49%) | 0.00% |
| Net margin | 6.15% | (2,594.20%) | 0.00% |
| Free cash flow margin | 8.42% | (1,924.59%) | 0.00% |
| Return on equity | 15.86% | (36.77%) | (56.36%) |
| Return on assets | 6.78% | (33.72%) | (48.04%) |
| Return on invested capital | 23.62% | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack